Neurosense Therapeutics Ltd
NRSN1.049USD
+0.009+0.84%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
25.80MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Neurosense Therapeutics Ltd Unternehmen
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Neurosense Therapeutics Ltd Informationen
BörsenkürzelNRSN
Name des UnternehmensNeurosense Therapeutics Ltd
IPO-datumDec 09, 2021
CEOMr. Alon Ben-Noon
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeDec 09
Addresse11 Hamenofim St.
StadtHERZLIYA
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl4672562
Telefon97299531142
Websitehttps://www.neurosense-tx.com/
BörsenkürzelNRSN
IPO-datumDec 09, 2021
CEOMr. Alon Ben-Noon
Führungskräfte von Neurosense Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+3.04%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+4.55%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+54.22%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+3.04%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+4.55%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+54.22%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: 3 hours ago
Aktualisiert: 3 hours ago
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Ben-Noon (Alon)
12.68%
Rimon Gold Assets Ltd
9.20%
Eisenberg (Or)
1.92%
Tracik (Ferenc)
0.76%
Citadel Advisors LLC
0.60%
Andere
74.85%
Aktionäre
Aktionäre
Anteil
Ben-Noon (Alon)
12.68%
Rimon Gold Assets Ltd
9.20%
Eisenberg (Or)
1.92%
Tracik (Ferenc)
0.76%
Citadel Advisors LLC
0.60%
Andere
74.85%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
16.35%
Corporation
9.20%
Hedge Fund
0.60%
Research Firm
0.52%
Investment Advisor
0.36%
Investment Advisor/Hedge Fund
0.31%
Andere
72.66%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
29
440.13K
1.76%
-1.60M
2025Q2
37
7.64M
31.03%
+143.76K
2025Q1
39
7.45M
37.28%
+353.50K
2024Q4
38
7.90M
34.02%
+1.29M
2024Q3
32
5.18M
22.45%
-1.31M
2024Q2
35
6.62M
30.57%
+1.57M
2024Q1
38
5.18M
33.20%
-953.28K
2023Q4
38
5.12M
32.81%
-1.05M
2023Q3
33
5.76M
47.99%
-945.27K
2023Q2
33
6.46M
53.11%
+1.06M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Ben-Noon (Alon)
3.18M
12.68%
+93.67K
+3.04%
Apr 07, 2025
Rimon Gold Assets Ltd
2.30M
9.2%
+2.30M
--
Dec 02, 2024
Eisenberg (Or)
480.92K
1.92%
+20.92K
+4.55%
Apr 07, 2025
Tracik (Ferenc)
189.62K
0.76%
+66.67K
+54.22%
Apr 07, 2025
Citadel Advisors LLC
149.24K
0.6%
+149.24K
--
Jun 30, 2025
Morgan Stanley & Co. LLC
79.90K
0.32%
+29.40K
+58.21%
Jun 30, 2025
Russek-Blum (Niva)
75.43K
0.3%
+10.00K
+15.28%
Apr 07, 2025
Leuchtenberger (Mark W)
64.00K
0.26%
--
--
Apr 07, 2025
Squarepoint Capital LLP
49.92K
0.2%
+49.92K
--
Jun 30, 2025
Meitav Dash Investments Ltd.
40.00K
0.16%
--
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
